These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drew Y; Plummer R Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. Yap TA; Sandhu SK; Carden CP; de Bono JS CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831 [TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Horvath EM; Szabó C Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Virág L; Szabó C Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530 [TBL] [Abstract][Full Text] [Related]
16. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Bowman KJ; Newell DR; Calvert AH; Curtin NJ Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322 [TBL] [Abstract][Full Text] [Related]
18. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281 [TBL] [Abstract][Full Text] [Related]
19. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605 [TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Sandhu SK; Yap TA; de Bono JS Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]